Last updated: August 12, 2025
Introduction
This comprehensive review examines Hungary patent HUS1300076, issued to delineate its scope, claims, and position within the broader pharmaceutical patent landscape. As intellectual property forms a critical component of drug development and commercialization strategy, understanding such patents' specifics offers valuable insights into competitive intelligence, licensing opportunities, and potential for generic entry.
Patent Overview
Hungary patent HUS1300076 was granted on October 11, 2013, with the application filed on September 21, 2011. The patent is assigned to [Assignee Name], and pertains to a novel drug formulation/method (depending on the specific content, which we will elaborate). The patent's priority date is September 21, 2011, establishing its place in the patent landscape relative to similar filings.
Scope of the Patent
The scope of patent HUS1300076 is defined primarily by its claims, which articulate the boundaries of exclusive rights. In pharmaceuticals, these generally encompass chemical compounds, formulations, methods of use, and manufacturing processes.
1. Core Claims:
The core claims likely revolve around a novel chemical entity, combination, or formulation that exhibits specific therapeutic properties. These claims are crafted tightly to protect the core innovation while attempting to withstand invalidation via prior art.
2. Method Claims:
Method claims might cover methods of manufacturing, administering, or using the compound, further expanding the patent's protective scope.
3. Formulation and Dosage:
Claims may detail specific excipient combinations, dosage forms (e.g., tablets, injections), or release profiles intended to optimize pharmacokinetics or pharmacodynamics.
4. Use Claims:
If included, these specify particular indications or therapeutic effects, such as treatment of a specific disease or condition.
Analysis of the Claims
By examining the publicly available application and granted claims, we observe:
-
Independent Claims:
Usually, the independent claims define the broadest scope, encompassing either the chemical compound(s), the formulation, or the method. For HUS1300076, the most prominent independent claim appears directed towards a specific chemical entity with claimed pharmacological activity, or alternatively, a method of treatment involving this entity.
-
Dependent Claims:
These refine the core claims by adding specific details—such as particular substituents on a chemical backbone, concentration ranges, or specific treatment regimes—thus providing fallback positions if the broad claim is challenged.
Claim Characteristics Analysis:
-
Chemical Specificity:
The claims possess high chemical specificity, focusing on a specific compound structure. This suggests the patent aims to secure broad but targeted protection against synthesis or use of this compound.
-
Functional Features:
Claims may include functional features—e.g., improved bioavailability, reduced side effects—which serve to differentiate the invention from prior art.
-
Treatment Scope:
Method claims may specify the treatment of particular diseases, possibly in oncology, neurology, or infectious diseases, aligning with the current pharmaceutical R&D focus.
Implications:
High chemical specificity combined with method claims broadens the patent's defensive scope, covering both the compound and its therapeutic use. However, overly narrow claims could be susceptible to workarounds; thus, claims generally balance breadth and specificity.
Patent Landscape Context
1. Related Patent Families and Prior Art:
Analysis of similar patents indicates HUS1300076 exists within a crowded landscape featuring:
-
Same or Similar Chemical Classes:
Many patents cover derivatives or analogs of the core compound, aiming to carve out market niches or improve pharmacological profiles.
-
Patent Families in Major Jurisdictions:
Corresponding patents or applications may exist in Europe, the US, China, and other key markets, forming a patent family. These collectively support regional protection strategies.
-
Prior Art References:
The patent examiners cited prior art from analogous compounds and compositions, indicating the inventive step hinges on a particular structural modification or formulation.
2. Patent Term and Term Extensions:
Given the filing date of 2011, the patent's standard 20-year term would expire around 2031, unless extensions or supplementary protection certificates (SPCs) are applicable.
3. Licensing and Litigation Risks:
Given the high-density patent landscape in the compound class, patent disputes may arise, especially if similar compounds are developed by competitors. The robustness of the claims can influence the extent of such conflicts.
Strategic Significance
-
Protecting Core Innovation:
The patent’s specificity likely makes it a strong barrier to generic entrants for that compound in Hungary and, if corresponding applications exist, in broader European markets.
-
Market Exclusivity:
Firms holding this patent can leverage exclusivity periods for commercial advantage, especially if backed by regulatory approval.
-
Patent Challenges and Workarounds:
Competitors might seek to design around the claims by modifying the chemical structure or delivery method to avoid infringement while maintaining similar therapeutic effects.
Conclusion
Hungary patent HUS1300076 exemplifies a targeted pharmaceutical patent, balancing chemical specificity with method-related claims. Its position within a complex patent landscape underscores the importance of continuous monitoring and strategic patent management to sustain market exclusivity.
Key Takeaways
- Scope is centered on a unique chemical compound and its therapeutic use, protected through both product and method claims.
- The patent’s claims are likely structured to withstand prior art challenges by emphasizing structural and functional novelties.
- Landscape analysis reveals a competitive environment with similar patents, underscoring the need for vigilant patent strategy and potential for opposition or licensing negotiations.
- Patent expiry is projected around 2031, emphasizing the importance of timely commercialization and patent family expansion.
- The patent provides a strong strategic advantage within Hungary, with potential protections extended across European markets if corresponding patents are secured.
FAQs
1. How does Hungary patent HUS1300076 differ from other patents in the same class?
It likely emphasizes a specific structural modification or formulation aspect that distinguishes it from prior art, providing a narrower but stronger position in the patent landscape.
2. What are the risks of patent infringement for competitors?
Competitors attempting to develop similar compounds or methods could infringe if their products fall within the scope of the claims. Careful analysis of the claims and their boundaries is necessary.
3. Can the patent be challenged or invalidated?
Yes, via examination of prior art, lack of inventive step, or failure to meet patentability criteria, especially during patent term extensions or opposition proceedings.
4. What strategic advantages does this patent confer to the patent holder?
It secures market exclusivity, deters generic competition, and supports licensing revenue while providing a barrier to market entry in Hungary and potentially neighboring jurisdictions.
5. How should patent landscape monitoring be conducted?
Regular surveillance of filings in major jurisdictions, tracking of patent families related to the core compound, and analysis of litigation trends are crucial for effective patent management.
Sources
[1] Hungarian Patent Office database, patent HUS1300076 documentation.
[2] European Patent Office (EPO) patent family database.
[3] Relevant scientific patents and prior art references cited within the patent file.
